Target intelligence / Profile preview

Mucin (respiratory tract)

Molecular classification
Glycoprotein, Secreted protein (for gel-forming mucins), Membrane-bound protein (for membrane-tethered mucins), Other (scaffold/structural component of mucus barrier)
01

Overview

Mucins are a large family of high molecular weight, heavily glycosylated glycoproteins secreted or expressed on the airway epithelium, forming the principal structural component of respiratory mucus[1][2][4][5]. They play crucial roles in maintaining airway hydration, trapping and clearing pathogens, modulating innate immune responses, and forming a physical barrier against irritants and microbes[1][2][3][4]. There are over 20 mucin genes in humans, with MUC5AC and MUC5B being the dominant secreted, gel-forming mucins in the respiratory tract, and MUC1, MUC4, and others forming membrane-associated mucins[1]. Abnormal mucin expression or structure is implicated in various airway diseases, and mucins are increasingly explored as therapeutic targets to modify mucus properties in conditions such as asthma, COPD, cystic fibrosis, and chronic bronchitis[1][4][5].

Other names
MucinsAirway mucinsRespiratory mucinsGel-forming mucins
02

Mechanism of action

Mucolytics: reduce disulfide bonds between mucin monomers to decrease viscosity Secretion inhibitors: reduce production or release of specific mucins Glycosylation modulators (experimental): alter mucin glycosylation to impact function

03

Biological functions

Barrier formation (protective mucus layer)Innate immune defense (trapping pathogens, modulating immune signaling)Lubrication of airway surfacesHydration regulationSignal transduction (for membrane-tethered mucins such as MUC1)Regulation of cell differentiation and proliferation (primarily based on studies in cancer)
04

Disease associations

Inflammation (e.g., asthma, chronic obstructive pulmonary disease (COPD))Infection (microbial defense, but also can be dysregulated in infection)Cancer (mucin overexpression, especially MUC1, linked with various cancers)Other respiratory diseases involving mucus overproduction or impaired clearance
05

Safety considerations

Excessive reduction of mucus can impair airway defense and increase infection riskPotential off-target effects from drugs targeting mucin production or structure
06

Interacting drugs

N-acetylcysteine (mucolytic agent)

4 more in the full profile.

07

Biomarkers

Concentration of MUC5AC and MUC5B in airway secretions (elevated in disease states)Expression patterns of specific mucin genes (e.g., MUC5AC in asthma, MUC5B in chronic bronchitis)

Beyond the preview

Go deeper on Mucin (respiratory tract).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mucin (respiratory tract).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call